Background Drugs with anticholinergic properties are considered potentially inappropriate in patients with cognitive impairment because harms-including delirium, falls, and fractures-may outweigh benefits. Objective To highlight opportunities to improve clinical decision making and care for patients with cognitive impairment and multiple chronic conditions, we identified distinct subgroups of patients with mild cognitive impairment (MCI) and dementia who had high cumulative anticholinergic burden and specific patterns of anticholinergic use.
Introduction
One in ten people age 65 years and older has Alzheimer's disease [1] , and the prevalence of dementia in the US is expected to reach 16 million by 2050 [2] . Mild cognitive impairment (MCI), often a precursor to dementia, may be present in up to 20% of people age 65 years or older, though prevalence estimates vary widely [3] . The vast majority of people with MCI and dementia have multiple chronic conditions (MCC) [4] . Providing optimal health care to older adults with MCC is challenging [5] , and cognitive impairment vastly compounds this difficulty [6] . The combination of MCI and dementia with other conditions leads to more medication use and is associated with greater risk of adverse drug events, hospitalization, and mortality [7, 8] .
Drugs with anticholinergic effects are prescribed to older adults for a wide variety of indications, including urinary incontinence, depression, pain, and insomnia. It is well recognized that cumulative anticholinergic burden arising from the use of multiple medicines with anticholinergic properties is associated with increased risk of adverse cognitive effects, falls, fractures, and death [9, 10] . Older adults with cognitive impairment are particularly vulnerable to anticholinergic side effects [11] . Higher cumulative use of medications with anticholinergic effects has been associated with increased risk of incident dementia in some studies [12] , though not others [13] , suggesting that anticholinergic burden could be a modifiable risk factor for dementia among individuals with MCI [14] .
Our objective was to describe the prevalence of cumulative anticholinergic burden in a population with dementia or MCI and MCC. We sought to identify distinct subgroups of patients who had high anticholinergic burden based on specific clusters of anticholinergic medications. Such profiles may suggest opportunities for targeted interventions to improve clinical decision making and care for patients with cognitive impairment and MCC.
Methods

Study Design and Population
This was a retrospective cohort study of older adult members of Kaiser Permanente Colorado (KPCO)-a non-profit, integrated delivery system that provides a coordinated continuum of services designed to meet all the health care needs of its members. The non-profit health plan serves approximately 670,000 members in 29 medical offices throughout Colorado. The KPCO Virtual Data Warehouse (VDW) was used to define a cohort of cognitively impaired individuals. The VDW is a standardized and quality controlled secondary observational database that incorporates data from the electronic health record (EHR), pharmacy fills, claims, membership, and administrative systems.
The study population consisted of KPCO members age 65 years or older with a diagnosis of dementia or MCI, as well as two or more additional chronic medical conditions out of 185, between May 1, 2014 and May 1, 2016 [16] . We required that members have at least 2 years of enrollment in a plan that includes benefits for preventative care and medications (e.g., original Medicare, Medicare HMO, HMO Plus, deductible/coinsurance, high deductible, Medicaid) prior to May 1, 2016. Alzheimer's disease, related dementias, and MCI were identified with a literature-based comprehensive list of ICD-9 and ICD-10 codes (Online Resource 1, see electronic supplementary material [ESM]) [17] . We assessed anticholinergic drug exposure in the 12 months prior to October 31, 2016 . This time frame ensured that all cohort members had a minimum of 6 months to experience medication exposure and a 24-month period to capture a claims-based diagnosis.
Assessment of Anticholinergic Use
Anticholinergic burden, as defined by the Anticholinergic Cognitive Burden (ACB) scale, was the primary variable of interest [15] . The ACB scale is one of several tools for quantifying the cumulative effect of individual drugs with anticholinergic properties. There is not yet data about which anticholinergic scale best predicts risk of adverse outcomes, particularly among those with MCI or dementia [18, 19] . We chose the ACB because it is most sensitive for identifying people with possible anticholinergic burden and has been externally validated [15, 20, 21] . On the ACB scale, each medicine is rated from 1 to 3. Medications with an ACB rating of 1 have serum anticholinergic activity, but their clinical impact on cognition is uncertain. Medications with an ACB rating of 2 or 3 have established, clinically relevant cognitive anticholinergic effects. The total score is the sum of ACB ratings of all medications taken by a person. We used pharmacy fill data to identify ACB medications dispensed between November 1, 2015 and October 31, 2016; this list did not include over-the-counter (OTC) medications. We did not include dispensed topical or inhaled products in this analysis [21] . Medication use was only assessed following the documented diagnosis of MCI or dementia. We calculated cumulative exposure to anticholinergics during a 12-month period as the average total daily ACB score for each patient [21] . The ACB score calculation incorporates duration of use in addition to the anticholinergic burden of each drug. We included all prescriptions for anticholinergic drugs in calculating ACB scores for the cohort; however, drugs prescribed for short periods of time had little effect on the high ACB scores in the analytic cohort. The numerator was the number of days during the study period that a person was supplied an anticholinergic medication multiplied by its ACB score; then summed across all ACB medications for that person. The denominator was the number of days that the person met eligibility criteria for the cohort in a 12-month period, beginning on November 1, 2015 or the date of the first MCI or dementia diagnosis, whichever came last, and ending on the date of death, disenrollment, or October 31, 2016, whichever came first (Fig. 1) . Average ACB scores can range from zero to high positive values; a continuous ACB score was used in calculating means and an ACB score rounded to the nearest integer was used in categorizing the cohort into low/no ACB use versus high ACB use.
Descriptive Analysis
We estimated the frequency and proportion of individuals with each characteristic for categorical variables and the mean, standard deviation, and median for continuous variables. Demographic and clinical characteristics were summarized overall and by dementia status. We used a two-sided alpha of p\0.05 for Chi square and t tests in comparing dementia and MCI groups.
Analysis
Research to identify these populations of patients who are more likely to receive anticholinergic medicines have typically used multivariable regression to identify patientlevel characteristics, such as demographics and diseases, that predict anticholinergic use [22, 23] . In contrast to multivariable regression, cluster analysis can be used to identify groups or 'clusters' of patients with similar patterns of medication use [24] [25] [26] . Such patient profiles and medication patterns can be useful clinically for tailoring care to meaningful subpopulations.
Among individuals with a rounded mean 12-month ACB score C 2, we used agglomerative hierarchical clustering to identify groups of individuals with similar anticholinergic prescription patterns (Online Resource 2, see ESM). In this method, each individual starts as a unique cluster, and the most similar individuals are joined in a stepwise fashion until there is only one cluster containing all observations. Individuals were clustered on the combination of anticholinergic drugs prescribed over a 12-month period. For each of the 68 ACB drugs present in our cohort, individuals were assigned a value of 1 if they were prescribed the drug and 0 if they were not. Since initial cluster solutions based on the 68 anticholinergic drugs did not produce homogenous and easy-to-interpret clusters, we underwent a variable simplification process. We grouped drugs together if they had similar therapeutic use and were generally not co-prescribed in the same individual (e.g., antipsychotics were grouped together, as were antidepressants). We explored the data and found that, contrary to our expectation, certain medications were often co-prescribed (e.g., trazodone and other antidepressants; quetiapine and other antipsychotics), so we kept these drugs separate from the others in their class. This variable simplification process resulted in 32 drug variables, on which we created a distance matrix and performed the final version of hierarchical clustering (Table 2) . Analyses were performed using SAS version 9.4.1 (SAS Institute, Inc., Cary, NC, USA). The study was reviewed and approved by the Kaiser Permanente Colorado Institutional Review Board.
Results
The cohort consisted of 13,627 people (14%) with either dementia or MCI as well as at least two of 185 other chronic conditions (Fig. 2) . MCI and dementia were first coded between 1998 and 2016. The mean age was 80 years (SD ± 8), 8090 (59%) were women, and the majority (81%; 11,080) were Caucasian. In total, 8083 (59%) people had dementia and 5544 (41%) had MCI (Table 1) . Sixty-seven percent of people with dementia and 73% of people with MCI were prescribed five or more unique medicines during the following 12-month observation period.
Nineteen percent of patients took at least one definite anticholinergic (ACB Level 2 or 3) during the 12-month cohort observation period. 50% of the population had a mean total daily ACB score of 0; 26% had a mean total daily ACB score of 1; 12% had a mean total daily ACB score of 2; 7% had a mean total daily ACB score of 3, and 5% had a mean total daily ACB score of 4 or more.
Anticholinergic Drug Clusters
We defined a sub-cohort of individuals with high ACB scores as those having mean total daily ACB scores C 2 (approximately the top quartile for all 13,627 patients-24%, 3257 patients). Among people with high ACB scores, cardiovascular medications were the main contributors to anticholinergic burden ( Table 2 ). The cluster analysis on the high ACB subcohort yielded a 13-cluster solution. We identified several clinically meaningful clusters of anticholinergic medications coprescribed during the 12-month observation period, as shown in Table 3 . In the most common cluster (1497 patients; 46% of those with ACB scores C 2), 98% of individuals were taking cardiovascular medications-bblockers (1197 patients; 80% of those in the cluster), diuretics (917 patients; 61%), and warfarin (846 patients; 57%). If taken simultaneously for the whole year, these three cardiovascular drugs would cumulatively result in an ACB score of 3. Individuals prescribed other drugs with anticholinergic properties often also took these common cardiovascular agents as well. For example, all of the 431 people in Cluster 2 had been prescribed bladder antimuscarinics (ACB Level 3) and many were also taking bblockers (172 patients; 40%), diuretics (90 patients; 21%), and warfarin (80 patients; 19%). All of the 311 patients in Cluster 4, which comprised 10% of the cohort, were taking 1497 (46) 431 (13) 322 (10) 311 (10) 198 (6) 161 (5) 113 (3) 79 (2) b-blockers antidepressants. Many of these patients were also taking bblockers, diuretics, and warfarin. Several clusters were comprised of multiple central nervous system (CNS)-active drugs. For example, virtually all of patients in Cluster 7 were taking bupropion and many were also taking trazodone, tricyclic antidepressants, other antidepressants, opioids/muscle relaxants, and benzodiazepines. All of the 198 patients in Cluster 5 were taking quetiapine and 36 patients (18%) were also taking other antipsychotics.
Discussion
Medications for many common chronic conditions contribute to high cumulative anticholinergic exposure. This is particularly relevant for individuals with impaired cognition plus common chronic medical conditions who are prescribed multiple medications and are vulnerable to anticholinergic side effects. Clinical profiles of patients at risk include those with dementia plus cardiovascular disease, depression, incontinence, and/or chronic pain. Increased attention to the anticholinergic medication burden of patients with these common clinical profiles may improve health outcomes for patients with impaired cognition.
Medications commonly used to treat cardiovascular conditions contributed substantially to anticholinergic burden in this population of older adults with cognitive impairment and MCC. This finding is consistent with previous research [27, 28] ; however, our study is one of the few to focus on patients with MCI or dementia and MCC in a large, community-dwelling US cohort. Multiple common cardiovascular drugs, such as furosemide, metoprolol, captopril, and digoxin, have anticholinergic properties. These are widely used to improve symptoms, prevent hospitalization, and prolong survival in patients with heart failure, including those with cognitive impairment [27] . These medications individually have low ACB scores, but were frequently co-prescribed, resulting in ACB scores of C 3. A large portion of anticholinergic burden may result from exposure to multiple ACB Level 1 drugs, and cumulative anticholinergic exposure from cardiovascular medicines may be an important contributor to the increased prevalence of cognitive impairment in people with heart failure [27, 29] .
We also found that patients with MCI and dementia were frequently exposed to multiple CNS-active drugs, including tricyclic antidepressants, selective serotonin reuptake inhibitors, benzodiazepines, anti-psychotics, and opioids. Depression, irritability, and sleep problems are common in people with dementia, with prevalence rates from 25 to 45%, and there has been an increase in CNSactive prescribing among older adults [30, 31] . However, the evidence for effectiveness of antidepressant pharmacotherapy in people with dementia is weak, and psychotropic medications may result in faster cognitive and functional decline in people with dementia [32] [33] [34] . This risk may be exacerbated by co-prescribing medications for other chronic conditions that contribute to anticholinergic burden (e.g., b-blockers, diuretics, and warfarin).
Our findings also highlight potential prescribing cascades that increase the risk of harm for people with dementia. For example, many patients were taking both diuretics and bladder antimuscarinics. Others were prescribed oral steroids, which may precipitate delirium or psychosis, together with antipsychotic medications such as quetiapine and sedating medications such as trazodone. Chronic pain, depression, and mobility impairments may lead to functional incontinence in patients with dementia, and this may be exacerbated by diuretic use. Incontinence may, in turn, lead to worsening depression. Bladder antimuscarinics used to treat incontinence may exacerbate balance problems and falls.
A strength of our study is the use of cluster analysis to identify distinct subgroups of patients with specific, clinically relevant combinations of medications, shedding light on prescribing patterns and coexisting conditions that require targeted approaches to care. Another strength of our study is the large sample of community-dwelling older adults with MCI and dementia. Previous research has documented high cumulative anticholinergic burden among people with dementia in nursing homes [23, 35, 36] , but less is known about anticholinergic prescribing practices among patients with impaired cognition (MCI and dementia) in non-institutional settings [22] . We found that 19% of community-dwelling older adults with MCI or dementia took at least one ACB Level 2 or 3 anticholinergic medication, which is consistent with other studies of older adults with impaired cognition [22, 23, 35, 37] . Our analysis was based on EHR data on pharmacy fills, which likely capture patients' use of medication better than prescription data or patient self-report [38] .
Our study also has some limitations. Prescribing patterns in an integrated healthcare delivery system with a shared EHR may not be representative of prescribing patterns in other settings. Our findings reflect the KPCO formulary and the existing best practice advisories for prescribing to older adults embedded in the EHR. OTC drugs, such as diphenhydramine (a Level 3 anticholinergic), could not be identified using our methods. We chose to use the ACB scale, though there is no gold standard for defining medications with anticholinergic effects, and the ACB does not account for dose. Our ability to distinguish between MCI and dementia using claims data was limited, and both may be under-reported within claims data [39] . However, the prevalence of MCI and dementia (6 and 9%, respectively) in our cohort was similar to studies in other populations [40] [41] [42] .
Multiple factors likely contribute to prescribing practices that increase anticholinergic burden. These include the desire to help patients with dementia and the dearth of effective treatment options, insufficient access to community-based long-term care services, caregiver burden in the face of behavioral symptoms of dementia, and fragmented prescribing by multiple clinicians [6, 43, 44] . Communication between healthcare providers is crucial to ensure that patients-particularly vulnerable older adults with dementia or MCI-receive medicines that will help them achieve their goals, but not medicines that are likely to be either harmful or unhelpful.
Conclusion
Decisions about whether medicines to treat chronic conditions are truly 'essential' in patients with dementia and MCI should continually be re-addressed, eliciting and respecting patient and family goals of care as cognitive changes occur. Clinicians should bear in mind that both MCI and dementia are independently associated with shortened life expectancy [45] , affecting decisions about therapies or tests with long lag times to benefit [46] . Once dementia is diagnosed, guideline-driven care of chronic conditions may be harmful, burdensome, or no longer concordant with patient and family goals. As a result of tools such as the Beers criteria [11] , clinicians may already be aware that highly anticholinergic drugs, such as oxybutynin, should be avoided in older adults with cognitive impairment. Future studies should investigate whether cumulative anticholinergic burden arising from low-level anticholinergic medicines is associated with adverse health outcomes in people with MCI and dementia. In the meantime, prescribers should be aware that many drugs prescribed to treat co-existing conditions in patients with cognitive impairment have secondary, unintentional anticholinergic effects. If used concurrently, these drugs might lead to clinically significant anticholinergic effects, negatively impacting the wellbeing of this vulnerable population.
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